Lupin’s arm launches Generic Trizivir Tablets

18 Dec 2013 Evaluate

Pharma Major Lupin’s  US subsidiary-Lupin Pharmaceuticals Inc. has launched  Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300mg (base) / 150mg / 300mg in the US after the US District Court for the District of Delaware ruled that the Lupin’s generic version of Trizivir did not infringe on patents. Lupin had earlier received approval for the same.

Lupin’s Abacavir Sulfate, Lamivudine Zidovudine 300mg (Base)/150mg/300mg Tablets are the AB?rated generic equivalent of ViiV Healthcare’s (ViiV) Trizivir Tablets, 300mg (base) / 150mg / 300mg and are indicated in combination with other antiretrovirals or alone for the treatment of HIV?1 infection. Lupin is the first applicant to file an ANDA for Trizivir Tablets and as such is entitled to 180 days of marketing exclusivity.

Trizivir Tablets, 300mg (base) / 150mg / 300mg had annual U.S sales of approximately $ 111.6 million (IMS MAT Sep, 2013).

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×